🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Act on Quality of Life in Patients With aortIc Stenosis

Recruitingn/aAges 18 Years - anyAllHospices Civils de Lyon
NCT06477042 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Aortic stenosis (AS) is a degenerative process affecting the aortic valve that leads to sclerosis of the valve and limits its opening during cardiac contractions. The prognosis is poorly, with survival rates of only 15-50% at 5 years. AS has a major impact on quality of life, with severely limiting symptoms (dyspnea, chest pain,…) often leading to repeated hospitalizations. It is the most common valvular disease in Europe and North America, and its prevalence is increasing as the population ages. In Europe, 17% of the population is aged 65 or over; in France, this proportion will reach 30% by 2030, corresponding to 16 million people. The incidence of aortic valve sclerosis (early stage AS) is around 25% at age 65, rising to 48% after age 75. The prevalence of aortic valve disease is likely to continue to rise, given the expected evolution of the age pyramid. There is no medical treatmen

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with symptomatic aortic stenosis (exertional dyspnea, angina, malaise/syncope) * Indication for TAVI (valve area 1 cm² or 1 cm²/m² body surface area or mean transvalvular aortic gradient \> 40 mmHg on ultrasound) validated in Heart Team * Charlson score ≥ 5 * Social health care insurance affiliation Exclusion Criteria: * Patient refusing TAVI procedure * CT scan not performed during the pre-TAVI assessment * Patient unable to understand or answer quality-of-life questionnaires * Pregnant or breast-feeding women * Patients participating in other interventional research that may interfere with the present study with an exclusion period still in progress * Persons under judicial protection * Patients under guardianship, curators or safeguard of justice
💊

What it tests

  • Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score
📍

Where

4 sites
Service de Cardiologie - CHU Clermont Ferrand
Clermont-Ferrand, France
Service de Cardiologie
Lille, France
Service de Cardiologie
Lyon, France
Service de Cardiologie - Institut Thorax Nantes
Nantes, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy